PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study-Reference-Cited by-同舟云学术

PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study

Published:2024-02 Issue: Volume:149 Page:106634
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Ferrarotto Renata,Swiecicki Paul L.,Zandberg Dan P.,Baiocchi Robert A.,Wesolowski Robert,Rodriguez Cristina P.,McKean Meredith,Kang Hyunseok,Monga Varun,Nath Rajneesh,Palmisiano Neil,Babbar Naveen,Sun William,Hanna Glenn J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference34 articles.

1. A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma;Goncalves;Oncotarget,2017

2. Stage means more than grade in adenoid cystic carcinoma;Spiro;Am J Surg,1992

3. Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to NOTCH1 inhibitors;Ferrarotto;J Clin Oncol,2017

4. Hanna G.J., ONeill A., Cutler J.M., Flynn M., Vijaykumar T., Clark J.R., et al. A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. Oral Oncol 2021;119:105366. 10.1016/j.oraloncology.2021.105366.

5. Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma;Kang;Clin Cancer Res,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adenoid cystic carcinoma: insights from molecular characterization and therapeutic advances;MedComm;2024-09